Greenwood Capital Associates LLC purchased a new stake in Novo Nordisk A/S (NYSE:NVO) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 85,945 shares of the company’s stock, valued at approximately $4,387,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in NVO. Clearbridge Investments LLC boosted its position in Novo Nordisk A/S by 42.3% in the first quarter. Clearbridge Investments LLC now owns 1,160,942 shares of the company’s stock worth $60,729,000 after purchasing an additional 344,989 shares during the last quarter. Jennison Associates LLC boosted its position in Novo Nordisk A/S by 89.5% during the second quarter. Jennison Associates LLC now owns 1,229,986 shares of the company’s stock worth $62,778,000 after purchasing an additional 580,944 shares during the period. Janus Henderson Group PLC increased its stake in shares of Novo Nordisk A/S by 11.4% in the first quarter. Janus Henderson Group PLC now owns 247,811 shares of the company’s stock worth $12,963,000 after purchasing an additional 25,382 shares in the last quarter. AE Wealth Management LLC purchased a new position in shares of Novo Nordisk A/S in the second quarter worth about $283,000. Finally, GYL Financial Synergies LLC purchased a new position in shares of Novo Nordisk A/S in the first quarter worth about $1,090,000. 7.36% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages recently commented on NVO. ValuEngine cut shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Tuesday. Deutsche Bank downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 target price on the stock. in a research report on Thursday, June 20th. Jefferies Financial Group lowered Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a report on Friday, August 30th. UBS Group reiterated a “buy” rating and issued a $355.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, June 19th. Finally, Zacks Investment Research upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price objective on the stock in a research note on Monday, July 15th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $111.58.

NYSE:NVO traded up $0.25 during mid-day trading on Wednesday, hitting $49.85. 10,286 shares of the stock traded hands, compared to its average volume of 1,282,028. The business’s 50-day moving average price is $50.77 and its 200 day moving average price is $49.93. The company has a quick ratio of 0.73, a current ratio of 1.04 and a debt-to-equity ratio of 0.06. The company has a market cap of $118.36 billion, a PE ratio of 19.79, a price-to-earnings-growth ratio of 2.16 and a beta of 0.57. Novo Nordisk A/S has a 12-month low of $41.23 and a 12-month high of $53.55.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Friday, August 9th. The company reported $0.61 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.61. Novo Nordisk A/S had a net margin of 32.16% and a return on equity of 75.16%. The business had revenue of $4.52 billion for the quarter, compared to analysts’ expectations of $4.41 billion. Analysts anticipate that Novo Nordisk A/S will post 2.45 earnings per share for the current fiscal year.

The company also recently declared a Semi-Annual dividend, which was paid on Tuesday, August 27th. Stockholders of record on Monday, August 19th were given a dividend of $0.318 per share. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 25.40%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Further Reading: Why do corrections happen?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.